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Abstract
Undifferentiated connective tissue disease (UCTD) was first defined by Leroy over 30 years ago.
UCTD is described as an autoimmune disease which presents similarly to other rheumatic
diseases but fails to meet laboratory requirements which indicate a specific disease such as
rheumatoid arthritis, systemic lupus erythematous, Sjogren's or scleroderma. Common signs and
symptoms manifested by patients with UCTD include arthralgias, myalgias, fatigue, fever,
Raynaud’s phenomenon and sicca like symptoms in addition to having a positive antinuclear
antibody (ANA) test. Often patients with these symptoms are referred to rheumatology.
Unfortunately, there is a shortage of rheumatology providers across the nation. Although
patients with UCTD have limited access to rheumatologists, there may be room for primary care
providers to safely and adequately treat their symptoms with the use of disease modifying
antirheumatic drugs (DMARDs) such as hydroxychloroquine. Evidence exists from recent
studies that support the use of DMARDs, NSAIDs and low dose corticosteroids in UCTD
patients to improve arthralgias, myalgias, fever, and functional limitations. Although the research
indicates that the majority of rheumatologists and primary care providers feel UCTD patients
should be referred to rheumatology, there is some evidence that primary care providers can also
initiate and manage the treatment of UCTD patients. In the absence of rheumatology, primary
care providers familiar with using DMARDs such as hydroxychloroquine can safely and
effectively provide treatment for these patients.
Keywords: Arthritis, Undifferentiated Connective Tissue Disease, Undifferentiated Systemic
Rheumatic Disease, Inflammatory Joint Disease, Disease Modifying Anti-Rheumatic Drugs,
hydroxychloroquine.
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Treatment of Undifferentiated Connective Tissue Disease with csDMARD’s through Primary
Care Providers in the Absence of Intervention via Rheumatology
Undifferentiated connective tissue disease (UCTD) is a form of autoimmune disease
which affects the adult population. Other terms for UCTD include incomplete lupus
erythematosus, undifferentiated systemic rheumatic disease, latent lupus, and potential lupus. (Al
Daabil, 2014). Rheumatology provides treatment to patients diagnosed with arthritic conditions
and other autoimmune and inflammatory conditions, such as rheumatoid arthritis, Sjogren's
syndrome, scleroderma and systemic lupus erythematosus. (Layton, 2015). Unfortunately, by
2025, data suggests that there will be a projected shortage of rheumatologists by 50% which will
likely cause strain to the health care sector. (Basen, 2016). Subsequently, patients with UCTD
face considerable wait times in pursuit of a consultation with a rheumatologist. West and West
(2014) pointed out that this has emerged as problematic because early pharmacological
intervention remains the standard of care for the majority of rheumatic disease patients.
The disease-modifying antirheumatic drugs (DMARDs), such as hydroxychloroquine, are
provided to patients with UCTD, systemic lupus erythematosus (SLE) and rheumatoid arthritis
(RA) and have been found to be effective. (West & West, 2014). Patients with these types of
clinical and laboratory findings are often referred to rheumatology for consultation. Primary care
providers play an essential part in early recognition and referral for patients presenting with
UCTD. Unfortunately, a shortage of rheumatology providers exists across the nation. Shortages
often result in rheumatology clinics screening patient referrals leading them to frequently accept
only those patients who have laboratory findings which indicate a specific rheumatic disease
such as RA or SLE.
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The focus of this scholarly project is to review the available literature to determine
whether intervention provided by primary care can effectively improve the symptoms of the
UCTD patients treated with the csDMARD hydroxychloroquine. The projected outcome is that
treatment of patients with UCTD using hydroxychloroquine in the primary care setting can
decrease pain and functional impairment in the absence of rheumatology intervention.
Statement of the Problem
Primary care providers deal with a multitude of diseases and illnesses that are difficult to
accurately diagnose. Often, patients display symptoms that are similar to certain diseases yet
laboratory findings do not support the suspected condition. For instance, UCTD is one of the
arthritis-related diseases with symptoms that are similar to other illnesses, yet laboratory findings
do not point to any one particular rheumatic disease. Unfortunately, there is a shortage of
rheumatologists to attend to the patients suffering from UCTD. (Bazsó et al., 2015). An article
written by Ryan Basen in 2016 describes a study done by the American College of
Rheumatology in 2015 which projected a decline in rheumatology labor force from 4,497 fulltime equivalents to 3,455. The study projected a shortage of 4,729 rheumatologists by 2030.
Additionally, 50% of the rheumatology workforce is expected to retire in the next 15 years which
further limits patient’s access to rheumatologists. (Basen, 2016). Consequently, the UCTD
patients who do not have access to rheumatologists frequently look to their primary care
providers for treatment. Nonetheless, it is not clear whether it is possible to decrease the inherent
symptoms of UCTD by offering early interventions using csDMARDs such as
hydroxychloroquine via a primary care provider. The use of csDMARDs by rheumatologists has
the potential to control rheumatic diseases, but the problem for UCTD patients is the lack of
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access to timely treatment by rheumatology. Delaying treatment may result in ongoing
symptoms such as but not limited to arthralgias, myalgias, and functional impairment.
Research Question
In the absence of rheumatology, can primary care providers effectively initiate and
appropriately manage patients with UCTD using conventional synthetic disease modifying
antirheumatic drugs, such as hydroxychloroquine, to reduce patient’s symptoms and functional
impairment?
Research Methods
An online databases search was carried out to complete this scholarly project. This
scholarly project used current research findings related to interventions used for treating UCTD
and the role primary care providers play in that treatment. Scopus, ScienceDirect, PubMed
Central (PMC), and ResearchGate were searched to provide scholarly and peer-reviewed articles
related to the treatment of UCTD patients with csDMARDs in primary care as part of early
intervention. There were a number of search terms used to identify specific articles on UCTD
treatment options and role of primary care in the management of connective tissue disease.
Search terms used included interventions used with UCTD, treatment of UCTD patients in
primary care, undifferentiated systemic rheumatic disease, early arthritis, the use of with
csDMARD for UCTD treatment, and effects of early intervention of UCTD using csDMARDs.
All article publications were written between 1999 and 2017, in English, and free to download
were included in this literature review. The relevant themes are clinical presentation of UCTD,
the prevalence of UCTD, treatment options for UCTD, prescription methods for UCTD, and
primary care's role in managing UCTD. Frequently, undifferentiated connective tissue disease
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was interrelated with undifferentiated systemic rheumatic disease. This often led to searches
related to early arthritis which is also considered an aspect of UCTD.
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Clinical and Serological Presentation of Undifferentiated Connective Tissue Disease
A wide array of physical findings can accompany a patient who presents to the clinic
with signs and symptoms of UCTD. Some of these include but are not limited to arthralgias,
Raynaud's syndrome, sicca syndrome, peripheral neuropathy, fatigue, vasculitis, malar rash,
uraturia, alopecia, oral/nasal lesions, and muscle weakness.
In 1980, Dr. Leroy, a rheumatologist at Department of Medicine, Medical University of
South Carolina, first identified undifferentiated connective tissue disease. At that time several
studies began to look further into the disease. In 1999, Mosca et al. completed a systematic
review of the current research data regarding the criteria in which a provider could use to
diagnose a patient with undifferentiated connective tissue disease. With this data, Mosca et al.
(1999) proposed criteria for undifferentiated connective tissue disease which included (a) signs
and symptoms suggestive of a connective tissue disease, but not fulﬁlling the criteria for any
deﬁned connective tissue diseases (CTD), (b) positive antinuclear antibody (ANA); (c) a disease
duration of at least one year, including early UCTD. Although the criteria was established in
1999, Bortoluzzi et al. (2017) found the classification criteria played a significant role in
identifying 392 patients with UCTD to be used in a long term study.
Likewise, Conti et al. (2010) found Mosca et al. (1999) criteria to be useful as well in
their study of UCTD patients. In addition to the criteria outlined in Mosca’s 1999 study, they
found several other clinical features which many UCTD patients had in common. The authors
identified 41 patients with early UCTD and followed them over a three year period. They found
the majority of their patients had more than 3 or 4 clinical symptoms simultaneously. Most
prevalent of the clinical manifestations included fatigue (83%), Raynaud’s syndrome (61%),
arthralgias (56%), muscle pains (56%), fever (51%), and polyarthritis (51%) (Table 1). A
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positive ANA and elevated ESR were the most frequent immunological findings. The study
showed mild changes in the clinical manifestation over a period of three years, but none were
statistically significant (p Value>0.05) except for erythema nodosum (p Value <0.05). However,
the study was limited by its small sample size.
In 2004, Mosca et al. completed a review of thirteen existing UCTD studies which looked
at a total of 1714 patients. The data was used to compile a profile of UCTD patients. The profile
suggested a UCTD clinical course which includes Raynaud’s phenomenon, sicca symptoms,
arthralgias, arthritis and mucocutaneous manifestations such as photosensitivity, malar rash, and
oral aphthous ulcers as well as a positive ANA. They determined that these disease
manifestations and a positive ANA should be present at least three years. Additionally, these
patients demonstrate no major organ involvement. Interestingly, the authors initially reported the
UCTD symptoms should be present for at least one year to exclude transitory illnesses but then
concluded at the end of their literature review that the symptoms and serological data should be
present for at least three years. This was different than Mosca et al. (1999) criteria which stated
that the symptoms had to be present for one year only.
A multicenter study by Danieli et al. (1999) researched 165 Italian patients diagnosed
with UCTD ranging in ages from 14-70 years old from ten different clinics. They found that
UCTD patients commonly presented with arthralgia, mucocutaneous abnormalities and
Raynaud’s phenomenon. The Danieli et al. (1999) study, also found evidence of a higher rate of
major end organ damage to include kidneys, lungs, and heart than previously identified. This is
opposite of the findings of Mosca et al. 2004, in which no end organ damage was identified.
While Danieli et al. (1999) study revealed physical findings that were suggestive of UCTD and
appeared to indicate possible specific autoimmune disease, laboratory findings did not always
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match physical findings. For example, the study found that although patients may have had a
positive rheumatoid factor (RF), the patients did not always have joint involvement.
Additionally, some patients were found to have positive anti-SSA/Ro and anti-SSB/La antibody
but did not present with sicca symptoms. The study found that physical symptoms with nonspecific immunologic abnormalities, otherwise known as UCTD, may ultimately develop into a
specific connective tissue disease. The Danieli et al. (1999) study was strengthened by the large
sample size involved in the study.
An article by Jessica Berman, MD, specializing in rheumatology at the Hospital for
Special Surgery, offers clear insight into the relationship of UCTD and with other
signs/symptoms of other well-known autoimmune diseases using a diagram (Figure 1). It
highlights how there is much overlap SLE, Scleroderma and RA symptoms with UCTD making
UCTD challenging to diagnose and treat. Although clinically, the patient presentation may
appear to be directed at a specific diagnosis, lab data does not support clinical findings.
Prevalence of Undifferentiated Connective Tissue Disease
Prevalence of UCTD is difficult to determine as many symptoms are vague which often
leads to under-reporting or misclassification of UCTD. Additionally, laboratory results do not
support a specific diagnosis which also can be frustrating for patient and provider alike. Often
diagnosing UCTD takes many years. An article in Autoimmunity Reviews done by Doria et al.
(2010) illustrated the difficulty in determining the onset of UCTD. Figure 2 demonstrates the
progressive nature of the disease which also highlights the difficulty in identifying subclinical
SLE or UCTD prevalence.
In 1999, Mosca et al. published a study of existing literature which determined that
between 20%-52% of patients seen by a rheumatologist with a connective tissue disease may
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have undifferentiated connective tissue disease. This range of patients is likely due to the
variable criteria used to diagnose UCTD. Mosca et al. (1999) study proposed criteria for
classification UCTD which is used today (Table 2). The study determined antinuclear antibodies
must be present, along with a disease duration of at least three years. It also suggested that
patient’s symptoms and ANA lasting less than three years be classified as having early UCTD. In
the study by Mosca et al. (2004), it was determined that the disease should have a duration of at
least three years. Secondary to the criteria and classification, the prevalence of UCTD remains
difficult to determine in the general population. The authors of the study found the absence of
validated and internationally accepted criteria for UCTD resulted in a limited survey of the
existing literature at that time. This remained consistent eleven years later with the study done
by Doria et al. (2010) which highlighted the challenges of diagnosing UCTD.
Like many other connective tissue diseases, UCTD patients are predominantly middleaged females. (Conti et al., 2010). Additional findings within the study concluded that after
three years of follow up, 52% of patients with diagnosed with UCTD maintained this diagnosis
while 27% demonstrated a clinical regression and 21% progressed to a defined connective tissue
disease such as SLE or RA. (Conti et al., 2010). The author’s study was limited secondary to
that it was observational only and follow up was limited to three years.
Al Daabil et al. (2014) collected retrospective data on patients seen at Brigham and
Women’s Hospital Lupus Center between 1 January 1992 and 31 December 2012. Bivariable
analyses and multivariable logistic regression models were used to analyze the data. They found
that of the 264 “potential lupus” patients followed over 20 years in a rheumatology clinic, only
21% were diagnosed with SLE (per ACR criteria) at the end of 6.3 years. Of the remaining
patients, 18% were diagnosed with another disease such as RA, Sjogren’s, and mixed connective
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tissue disease while 56% were still considered to have “potentials SLE” otherwise known as
undifferentiated connective tissue disease. The study was strengthened by its study of a large
population over a period of greater than six years and contained well documented clinical data.
A retrospective study by Bortoluzzi et al. (2017) reviewed the charts of 392 UCTD
patients which were referred to their rheumatology clinic. The patients were selected using the
criteria set by Mosca et al. 1999. They found that patients who presented with acute or subacute
skin rash, inflammation of the serous tissue and positive antiphospholipid antibodies were the
most likely to progress to SLE. Of the 283 patients originally classified as having UCTD, over
the 15 year period 260 patients continued to be classified as having stable UCTD while 23
patients were eventually diagnosed with SLE. The study used 2012 Systemic Lupus
Collaborating Clinics (SLICC) criteria to classify patients as having SLE (Table 3). This was an
important aspect of Bortoluzzi et al. (2017) study due to the number of overlapping symptoms of
UCTD and SLE. Using the more sensitive SLICC classiﬁcation criteria for SLE, this increased
the number of SLE diagnoses which were otherwise labeled as “stable” UCTD. The study by
Bortoluzzi et al. (2017) was strengthened by its large population, and its lengthy duration yet was
limited by its retrospective design.
A review of the literature by Mosca et al. (2011), suggested that 20% of newly referred
patients to rheumatology may fall within the undifferentiated profile excluding rheumatoid
arthritis. After surveying numerous studies, they concluded that the majority of UCTD patients
were female (80-99%) and age of disease onset ranged from 32-44 years of age. After much
review, they found that of those presenting with UCTD symptoms, up to 70% may remain
undifferentiated. Although, this can be identified as stable UCTD authors suggested the
importance that these patients be monitored for possible disease progression. The percentage of
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patients which remained undifferentiated in Mosca et al. (2011) study was 70% which was
considerably different than the Conti et al. (2010) in which only 52% of patients remained
undifferentiated.
In studying the prevalence of UCTD, as with many other autoimmune diseases, Danieli et
al. (1999) found that UCTD predominately affects females over males (12:1). They found that
the majority of those affected began having significant symptoms in their 40’s. The study
suggested that a screening tool or scoring system could further help to identify those patients
with UCTD. Likewise, Mosca et al. (2011) expressed some difficulty in determining the
prevalence of UCTD and suggested adding exclusion criteria which could further help identify
disease onset.
Prescriptive Treatment Methods for Undifferentiated Connective Tissue Disease
Data presented by Mosca et al. (2004) indicated that most UCTD patients were
adequately treated by using low dose corticosteroids (53%) and hydroxychloroquine (11%).
Additional studies conducted over time by Mosca et al. (2012) saw an increase in antimalarial
use and rare use of immunosuppressive drugs in treating UCTD patients. Treatment consisted of
low-dose corticosteroids (36%) and antimalarial drugs (52%) while 16% of UCTD patients were
not being treated with prescription medications.
Conti et al. (2010) concluded that close follow up and use of hydroxychloroquine,
NSAIDs, and low dose corticosteroids was sufficient to maintain UCTD in an inactive status.
The treatment regime allowed for control disease activity which included reduction of
arthralgias, functional limitations, myalgias and fever in many of their case study patients.
Unfortunately, the study could not determine if a moderately aggressive form of therapy could
prevent the evolution of the disease. However, the study did show that the prescriptive therapies
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offered positive results concerning arthralgias, functional limitations, myalgias, and fever. The
authors suggested early UCTD patients have strict follow up at least every six months. They
also recommended clinical and diagnostic testing before starting treatment and during follow-up.
A study of 130 military service members was done by James et al. (2007) in which
serological, demographic and clinical manifestations data was collected on soldiers with nonorgan damaging early lupus. The main focus of the study was to see if progression from early
lupus to SLE was delayed by treatment with hydroxychloroquine, prednisone, or ibuprofen.
Patients treated with hydroxychloroquine before being diagnosed with SLE had a statistically
signiﬁcant increase (p = 0.018) in the time between the symptom onset and SLE diagnosis
compared to patients who were not treated with hydroxychloroquine before diagnosis (median
time: 1.08 versus 0.29 years). (James, 2007). Additionally, the study showed using prednisone
with UCTD delayed the development of SLE. The research appeared to indicate that the use of
hydroxychloroquine and prednisone may have a synergistic effect and prove to be more
beneficial in delaying the onset of SLE. The study was limited by the fact that it was not a
randomized trial and that the natural evolutional history of untreated possible SLE was unknown.
The study would suggest that a more aggressive approach to treating non-organ early lupus with
nontoxic hydroxychloroquine is warranted.
Puchner et al. (2016) carried out a study of Australian rheumatologists and general
practitioners to measure the perceptions of the general practitioners and rheumatologists
concerning the issue of the prescribing techniques for connective tissue disease. When
concerning single or multi-joint inflammatory arthritis 1,215 of the general practitioners (100%)
and 101 of the rheumatologists (92%) recommended lab tests before referring to a
rheumatologist. With regards to connective tissue disease, 78% of general practitioners and 90%
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of rheumatologists recommended referral to a rheumatologist even if the patient did not show
signs of joint inflammation. When treating inflammatory rheumatic disease, 43% of general
practitioners would always prescribe glucocorticoids, yet only 11% of rheumatologist were in
favor of general practitioners prescribing glucocorticoids before to referral at all (p<0.001).
Additionally, 32% of rheumatologists discouraged general practitioners from prescribing
glucocorticoids as the medication may mask disease symptoms. (Puchner et al., 2016). Overall,
rheumatologists and general practitioners agree that only rheumatologists should initiate
treatment using conventional synthetic disease-modifying drugs (DMARDs) such as
hydroxychloroquine when treating rheumatic diseases, yet one-third of both also agreed that
when rheumatology availability is limited, then csDMARDs could also be initiated by a general
practitioner. (Puchner et al., 2016).
Smolen (2013) found that Target-to-Treat (TTT) approach in treating inflammatory
rheumatic disease, specifically rheumatoid arthritis, via the use of DMARD was effective in
improving the health and patient's outcomes. Smolen (2013) found using TTT (Figure 3)
resulted in high response rates treating with DMARD plus glucocorticoid use. Often time’s
inflammatory disease activity is reflected with complaints of joint pain, fatigue, mucocutaneous
irritations, etc. Up to 40% of patient with active disease complaints who have a normal CRP,
ESR, and RF at disease onset. (Sokka et al., 2009). Disease activity can easily be assessed by
using the RAPID3 questionnaire which is free online. This could be used by primary care
providers to monitor disease activity allowing for treatment modifications during follow up
visits.
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Role of Primary Care in the Management of Undifferentiated Connective Tissue Disease
In the absence of rheumatologists, primary care providers play a crucial role in the
management of suspected connective tissue disease and other rheumatic diseases. Badley,
Canizares, Gunz, and Davis (2015) studied the significance of accessing primary care physicians
when managing inflammatory rheumatic connective tissue disease, especially in the absence of
rheumatologists. The multi-level study was conducted in Ontario, Canada. The findings indicated
that the visits to physicians for any form of inflammatory joint pain remained at 130.4 per 1,000
population, compared to rheumatologists who were 13.4 per 1,000 population. (Badley et al.,
2015). Thus, 10.3% of the patients made at least one visit to primary care for inflammatory
arthritis. The findings further showed that most patients with low socioeconomic status or those
living in areas with limited access to primary care physicians were less likely to have office visits
to rheumatologists. Badley et al. (2015) showed that the median geographic availability index of
rheumatologists indicated that 11 out of the 105 health planning areas located had no availability
for a rheumatologist. In spite of skewed access to a rheumatologist, 75% of the population lived
near a facility with a rheumatology department. The findings demonstrated that patients with
limited access to physicians in the primary care setting are severely affected by the illness
compared to those living within access areas. Additionally, primary care providers were less
likely to use csDMARDs to treat connective tissue disease symptoms.
Puchner et al. (2016) established that DMARD treatment in primary care was imperative
because unnecessary referrals of patients diagnosed with rheumatic condition increased the work
overload in rheumatology practices. Badley et al. (2015) noted that adequate patient access to
rheumatologists was critical because early treatment of early connective tissue disease with
DMARDs and biologic agents improved clinical outcomes. Moreover, the use of DMARDs and
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biologic agents improved a patient’s quality of life, functional status, reduced sick leave and
decreased job loss. Delayed treatment initiation of DMARDs therapy has the potential to result
in poor outcomes according to James et al. (2007). Although disease-modifying therapy is not
commonly initiated in primary care by primary care physicians, DMARDs are recommended,
especially when timely access to rheumatologists is limited. On the other hand, timely access to
rheumatologists can significantly reduce joint pain, swelling, global pain, morning stiffness,
functional status, and improve symptom control.
Discussion
Current literature suggests that primary care providers play a significant role in UCTD
treatment because they are frequently the only and first point of contact for many patients.
Puchner et al. (2016) and Badley et al. (2015) identified the role of primary care providers to be
significant in treating early connective tissue disease due to the rheumatology shortage. James el
al. (2007) also found this to be true. Therefore, it may be up to the primary care physicians to
make use of their clinical knowledge to establish a treatment regimen to meet patient's needs.
Moreover, even when primary care physicians referred patients with UCTD, to rheumatologists
in known shortage areas, the referral may be denied as the rheumatologists are frequently
overwhelmed with treating known rheumatic diseases. Thus, a shortage of rheumatologists has
resulted in long wait times in the healthcare setting for rheumatology visits. Yet Puchner et al.
(2016) found that the primary consensus between rheumatologists and general practitioners is
that a patient must be referred to a rheumatology expert to seek the necessary treatment.
Similarly, a small percentage of the primary care physicians acknowledged having initiated
DMARD therapy, but the majority of general practitioners pointed out that they would prescribe
DMARDs.
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Moreover, early identification and treatment of UCTD by a primary care provider can
result in a decline in disease progression, pain, possible joint destruction and functional
impairment when compared to delayed intervention via rheumatology. Studies reviewed for this
project indicated that possible delays in referrals to rheumatology resulted in long-term harm,
including joint inflammation and destruction. Primary care providers can initiate treatment with
DMARDs in the absence of treatment provided through rheumatology. Using csDMARDs are
effective in the treatment of UCTD which can lead to improving a patient’s quality of life.
However, the reviewed literature indicates that primary care physicians will commonly continue
to use DMARDs, although only a minority initiate them. Discomfort in prescribing DMARDs is
linked with difficulties in accessing rheumatology referrals in primary care. Early administration
of DMARD can improve the painful symptoms of UCTD and possibly reduce the progression of
the disease from UCTD to a definitive connective tissue diagnosis. Limitations to early
treatment by primary care providers would include the providers comfort level and knowledge of
DMARD therapy use.
The literature on health outcomes for patients receiving care from rheumatologists
compared primary care providers have supported the need for referrals. Timely consultation with
a specialist can result in the initiation of medications and improved symptom control. The current
literature has established that early use of DMARDs is common in primary care, but 40% of
those primary care physicians who prescribe DMARDs reported that delayed initiation is
suitable. Thus, this approach of 'wait and see' indicates a primary care physician’s lack of
urgency in the aggressive treatment of UCTD and may result in delayed referral to a
rheumatologist.
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Overall, the current studies have provided significant data supporting the use of
DMARDs in treating UCTD, but there is minimal evidence that supports the use of DMARDs by
primary care providers. Although there have been numerous studies siting criteria used to
diagnose UCTD, no specific studies were found indicating how confident primary care providers
are in diagnosing and treating the disease. Additionally, data indicates that rheumatologists
overwhelmingly feel that it is the role of rheumatology providers to diagnose and initiate
treatment of connective tissue disease. Studies show that in some cases of stable disease, it may
be appropriate for primary care providers to continue with DMARD use. In searching for data,
no studies were found indicating adverse patient outcomes nor positive patient outcomes in cases
where primary care providers took the lead in diagnosing and treating UCTD with DMARDs.
After a comprehensive review of the available and current literature, the role of the primary care
provider in initiating treatment for these patients remains unclear. It can be surmised that the use
of DMARDs is likely based in each providers comfort level and knowledge of DMARDs in
treating UCTD. Future studies on the use of DMARDs by primary care providers in treating
UCTD is recommended.
Applicability to Clinical Practice
Adequate patient access by patients to rheumatologists is critical because early treatment
of connective tissue disease via DMARDs provides the opportunity to intervene and improve
quality of life. Current literature has established that the use of csDMARD result in low disease
activity and improve remission rates. On the other hand, delays treatment with DMARDs is
linked to worse outcomes such as poor health and depression. Thus, in clinical practice, these
findings are necessary as they can be used to encourage primary care providers to initiate
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disease-modifying therapy in cases where timely access to rheumatologists is limited.
Subsequently, negative outcomes can be reduced, and health of patients with UCTD improved.
Given the gap and lack of accessibility to rheumatologists by patients with UCTD, health
care sector could collaborate with primary care providers to offer formal training to improve
patients' outcomes and reduce instances of joint pain, debility, decreased quality of life and
depression. As recommended by Solomon et al. (2014), rheumatology organizations may put into
consideration the possibility of working with physician assistant programs and schools of nursing
to integrate rheumatology into the curriculum. Subsequently, primary care providers frequently
have the first contact with patients and therefore could be in a position to provide services
offered by rheumatologists. The presence of primary care providers skilled in rheumatology can
reduce waiting times in rheumatology outpatient practices and clinics. Subsequently, earlier
diagnosis and earlier incorporation of therapy could be realized thus leading to better patient
outcomes. Additionally, delays in consulting a general practitioner, waiting times for
appointments, delays in referral to a rheumatologist, and delays in identifying a correct diagnosis
by rheumatology-trained personnel after referral could be improved.
Early intervention using csDMARDs offered by primary care providers can improve the
symptoms of UCTD patients. Primary care providers have an opportunity to greatly impact the
progression and detrimental effects of UCTD using early csDMARDs therapy. Education can be
used to increase knowledge and awareness which can improve access to safe and timely
treatment. (Brennan-Olsen et al., 2017). The majority of primary care physicians are
uncomfortable with the identifying and managing UCTD with DMARDs, but recommendations
by clinical organizations could improve the confidence. Future directions for research that
focuses on UCTD care improvement may include altering the design of educational programs for

TREATMENT OF UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE
primary care providers such that they have greater comfort prescribing DMARDs. (Gerneau et
al. 2012). There continues to be a need for improving awareness and education regarding
diagnosing and treating UCTD patients in primary care where early treatments with DMARDs
make a significant impact on a patient’s health and quality of life.
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Figure 1: UCTD Overlap

Berman, J. R. (2017, July). Undifferentiated Connective Tissue Disease: In-Depth Overview.
Retrieved from https://www.hss.edu/conditions_undifferentiated-connective-tissuedisease-overview.asp.
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Table 1: Clinic Features of UCTD
Clinical Features
Fatigue
Raynaud’s syndrome
Arthralgia
Muscle pains
Fever
Polyarthritis
Xerophthalmia
Xerostomia
Weight loss
Thyroiditis
Oral aphthosis
Lymphadenopathy
Urticaria
Synovitis
Serositis
Photosensitivity
Erythema nodosum
Other

% Patients
83
61
56
56
51
51
29
27
24
19
17
17
17
15
14
12
9
7

Conti, V., Esposito, A., Cagluiuso, M., Fantauzzi, A., Pastori, D., Mezzaroma, I., Aiuti, F. (2010).
Undifferentiated Connective Tissue Disease-An Unsolved Problem: Revision of
Literature and Case Studies. International Journal of Immunopathology and
Pharmacology, 23(1), 271-278. doi:10.1177/039463201002300125.
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Table 2: Suggested preliminary classification criteria for UCTD.
1. Signs and symptoms suggestive of a connective tissue disease, but not fulfilling the criteria for
any of the defined CTDs for at least three years.
2. Presence of antinuclear antibodies determined on two different occasions.
* If the disease duration is less than three years, patients may be defined as having an early
undifferentiated connective tissue disease (EUCTD).
Mosca, M., Neri, R., Bombardieri, S. (1999). Undifferentiated connective tissue diseases
(UCTD): a review of the literature and a proposal for preliminary classification criteria.
Clinical and Experimental Rheumatology 1999 (17):615–620. Retrieved from
https://pdfs.semanticscholar.org/233b/6c55c10fb5c8b880f57e039de07be53f80d6.pdf.
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Figure 2: Autoantibodies Related to Onset of Diagnosis

Doria, A., Zen, M., Canova, M., Bettio, S., Bassi, N., Nalotto, L…& Iaccarino, L., (2010). SLE
diagnosis and treatment: When early is early. Autoimmunity Reviews 10(1): 55-60.
doi:10.1016/j.autrev.2010.08.014.
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Figure 3: Target to Treat- Generic Model

Solomon, D. H., Yelin, E., Katz, J. N., Lu, B., Shaykevich, T., & Ayanian, J. Z. (2013). Treatment
of rheumatoid arthritis in the Medicare Current Beneficiary Survey. Arthritis Research &
Therapy, 15(43), 1-7. doi:10.1186/ar420.
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Table 3: 2012 SLICC Classification Criteria for SLE

Petri, M., Orbai, A.-M., Alarcón, G. S., Gordon, C., Merrill, J. T., Fortin, P. R., … Magder, L. S.
(2012). Derivation and Validation of Systemic Lupus International Collaborating Clinics
Classification Criteria for Systemic Lupus Erythematosus. Arthritis and Rheumatism,
64(8), 2677–2686. http://doi.org/10.1002/art.34473.
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